207.64
前日終値:
$208.71
開ける:
$207.95
24時間の取引高:
215.70K
Relative Volume:
0.47
時価総額:
$12.79B
収益:
$393.98M
当期純損益:
$-367.45M
株価収益率:
-32.99
EPS:
-6.293
ネットキャッシュフロー:
$-460.07M
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
+6.72%
6か月 パフォーマンス:
+34.94%
1年 パフォーマンス:
+63.16%
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ASND
Ascendis Pharma A S Adr
|
207.55 | 12.64B | 393.98M | -367.45M | -460.07M | -6.293 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
409.81 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
475.59 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.71 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
816.50 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
316.14 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-03 | 再開されました | Morgan Stanley | Overweight |
2025-05-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2025-04-16 | 開始されました | RBC Capital Mkts | Outperform |
2025-01-07 | 開始されました | UBS | Buy |
2024-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
2024-06-25 | アップグレード | TD Cowen | Hold → Buy |
2024-05-31 | 開始されました | Stifel | Buy |
2023-12-20 | 開始されました | Jefferies | Buy |
2023-06-14 | 再開されました | Credit Suisse | Neutral |
2023-04-05 | ダウングレード | Oppenheimer | Outperform → Perform |
2023-04-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-03 | ダウングレード | Credit Suisse | Outperform → Neutral |
2022-10-20 | 開始されました | Goldman | Buy |
2022-08-30 | 再開されました | Berenberg | Buy |
2022-03-28 | 再開されました | Wedbush | Outperform |
2022-03-15 | アップグレード | BofA Securities | Neutral → Buy |
2022-03-01 | 開始されました | Citigroup | Buy |
2022-02-14 | アップグレード | Oppenheimer | Perform → Outperform |
2022-01-06 | 開始されました | Cowen | Market Perform |
2021-12-08 | 開始されました | Wells Fargo | Overweight |
2021-10-20 | ダウングレード | BofA Securities | Buy → Neutral |
2021-03-30 | ダウングレード | Oppenheimer | Outperform → Perform |
2021-03-11 | 再開されました | Stifel | Buy |
2020-12-17 | 開始されました | Berenberg | Buy |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-03-20 | 開始されました | Oppenheimer | Outperform |
2019-10-11 | 開始されました | Morgan Stanley | Overweight |
2019-03-25 | 開始されました | Evercore ISI | Outperform |
2019-01-24 | 開始されました | Cantor Fitzgerald | Overweight |
2019-01-24 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2018-06-26 | 開始されました | Stifel | Buy |
2018-04-02 | 繰り返されました | Leerink Partners | Mkt Perform |
2017-05-11 | 開始されました | JP Morgan | Overweight |
2017-03-09 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
2017-02-09 | 開始されました | Credit Suisse | Outperform |
2016-09-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Ascendis Pharma A S Adr (ASND) 最新ニュース
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl
Ascendis Pharma reports positive results from hypothyroid trial - MSN
Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
Canaccord holds Ascendis Pharma stock at $84 target - Investing.com
BofA raises Ascendis Pharma stock target to $216 - Investing.com
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN
Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl
BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India
Ascendis Pharma stock rises following FDA priority review - Investing.com
FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com
Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com
Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India
Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India
Ascendis Pharma grants new employee warrants - Investing.com
Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com
Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX
Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com
Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com
Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com
Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Rising Momentum: Is Ascendis Pharma a Hidden Gem? - StocksToTrade
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Ascendis Pharma A S Adr (ASND) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):